Targeting immune checkpoints in brain tumors
Targeting Lag-3 and PD -1 in Myeloid Cells of GBM
['FUNDING_R01'] · STANFORD UNIVERSITY · NIH-11056162
This study is looking at a new way to help your immune system fight glioblastoma, a tough brain tumor, by using a special treatment that targets certain checkpoints to boost your body's ability to attack the cancer, and if you join, you might get access to promising new therapies.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11056162 on ClinicalTrials.gov |
What this research studies
This research investigates the use of immunotherapy to enhance the immune response against glioblastoma (GBM), a highly aggressive brain tumor. The approach focuses on blocking specific immune checkpoints, PD-1 and LAG-3, to reduce immunosuppression in the tumor environment and activate T cells that can attack the cancer. By studying the mechanisms of this dual therapy, the research aims to improve patient outcomes and potentially increase survival rates for those affected by GBM. Patients participating in this research may receive novel treatment options that have shown promise in early trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who have limited treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and better treatment options for patients with glioblastoma.
How similar studies have performed: Preliminary findings from similar approaches have shown promising results, indicating potential efficacy in treating glioblastoma.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIM, MICHAEL — STANFORD UNIVERSITY
- Study coordinator: LIM, MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer